The firm reported revenue of $77,000 for the three months ended September, above the $4,000 reported in the corresponding quarter of 2024, but below an analyst estimate of $5.03 million, according to data from Fiscal AI.
CollPlant (CLGN) Q2 2025 results miss analyst estimates, with revenue of $180K far below expectations. Shares fell in pre-market trading on the earnings disappointment.
CLGN stock results show that CollPlant Biotechnologies beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
